S
Silence Therapeutics PLC (SLN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$19.80
+0.00 (+0.00%)
Market Cap: $1.23B
Last updated: Nov 17, 2026 at 4:15 PM ET
Silence Therapeutics PLC (SLN) Valuation Multiples
Silence Therapeutics (SLN) trades at 882.5x sales and 5.1x book value. Its P/S of 882.5x is above its 5-year median of 7.5x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 882.5x |
| Price to book | 5.1x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 882.5x | 7.5x | N/A |
| P/B | 5.1x | 3.2x | N/A |
Valuation History
Over the 6 year ends shown, its P/S ranged from 2.0x in 2024 to 104.2x in 2025. 2025 was the highest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $6.08 | 104.2x | 1.1x |
| 2024 | $6.88 | 2.0x | 0.8x |
| 2023 | $17.37 | 6.7x | 8.2x |
| 2022 | $15.25 | 7.5x | 6.8x |
| 2021 | $23.89 | 41.7x | 61.5x |
| 2020 | $22.00 | 85.6x | 51.3x |
P/E history is shown only for companies that report in US dollars.
Frequently Asked Questions About SLN
What is SLN's price to sales ratio?
Silence Therapeutics has a price to sales ratio of 882.5x.
SLN pages: Overview, Charting, Statistics, Valuation, Competitors